Titan Pharmaceuticals Inc Quick Ratio (TTNP) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Titan Pharmaceuticals Inc   (NASDAQ: TTNP)

Titan Pharmaceuticals Inc 's Quick Ratio

TTNP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Titan Pharmaceuticals Inc 's Cash & cash equivalent grew by 44.11 % in the Q2 2025 sequentially, while Current Liabilities decreased, this led to improvement in Titan Pharmaceuticals Inc 's Quick Ratio to 10.66, above Titan Pharmaceuticals Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 21 other companies have achieved higher Quick Ratio than Titan Pharmaceuticals Inc in second quarter 2025. While Quick Ratio total ranking has improved so far during the Q2 2025 to 241, from total ranking in the first quarter 2025 at 351.

Explain Quick Ratio?
How much Cash & cash equivalents TTNP´s has?
What are TTNP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TTNP Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -26.12 % -50.09 % -66.55 % -80.12 % -80.72 %
Y / Y Cash & cash equivalent Change -31.5 % -68.42 % -58.12 % -58.02 % 3797.14 %
Quick Ratio MRQ 10.66 6.97 5.86 9.16 11.49
TTNP's Total Ranking # 241 # 351 # 481 # 315 # 241
Seq. Current Liabilities Change -5.73 % -42.24 % 30.19 % 4.21 % -36.31 %
Seq. Cash & cash equivalent Change 44.11 % -31.3 % -16.71 % -16.94 % -33.56 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 22
Healthcare Sector # 120
Overall Market # 241


Quick Ratio Statistics
High Average Low
11.49 3.02 0.06
(Jun 30 2024)   (Jun 30 2023)




Financial Statements
Titan Pharmaceuticals Inc 's Current Liabilities $ 0 Millions Visit TTNP's Balance sheet
Titan Pharmaceuticals Inc 's Cash & cash equivalent $ 3 Millions Visit TTNP's Balance sheet
Source of TTNP's Sales Visit TTNP's Sales by Geography


Cumulative Titan Pharmaceuticals Inc 's Quick Ratio

TTNP's Quick Ratio for the trailling 12 Months

TTNP Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -66.96 % -73.95 % -76.73 % -68.94 % -55.77 %
Y / Y Cash & cash equivalent TTM Growth -56.28 % -41.92 % 2.39 % 66.29 % 190.99 %
Quick Ratio TTM 7.86 8.24 9.32 7.48 5.94
Total Ranking TTM # 3341 # 2252 # 3078 # 2979 # 2796
Seq. Current Liabilities TTM Growth -6.25 % -15.83 % -35.2 % -35.38 % -26.07 %
Seq. Cash & cash equivalent TTM Growth -10.51 % -25.57 % -19.25 % -18.71 % 18.88 %

Quick ratio ranking by company, industry and sector >> Back to TTNP Financial Strength Comparisons >> Go to Compare TTNP Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in TTNP's Current Liabilities to $0.26 millions, cumulative Quick Ratio to 7.86 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 154 other companies have achieved higher Quick Ratio than Titan Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from 2252 to 3341.

Explain Quick Ratio?
How much Cash & cash equivalents TTNP´s has?
What are TTNP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 155
Healthcare Sector # 887
Within the Market # 3341


trailing twelve months Quick Ratio Statistics
High Average Low
9.32 2.83 0.89
(Dec 31 2024)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Hillevax Inc   25.96 $ 159.547  Millions$ 6.147  Millions
Tectonic Therapeutic Inc   25.30 $ 287.381  Millions$ 11.361  Millions
Tourmaline Bio Inc   24.04 $ 239.234  Millions$ 9.950  Millions
Cg Oncology Inc   21.76 $ 661.052  Millions$ 30.381  Millions
Artiva Biotherapeutics Inc   20.19 $ 142.400  Millions$ 7.053  Millions
Kymera Therapeutics Inc   19.64 $ 665.445  Millions$ 33.874  Millions
Crispr Therapeutics Ag  16.49 $ 1,721.237  Millions$ 104.362  Millions
Apogee Therapeutics Inc   16.02 $ 505.420  Millions$ 31.551  Millions
Cidara Therapeutics Inc   15.80 $ 510.575  Millions$ 32.318  Millions
Qiagen N v   15.12 $ 1,098.918  Millions$ 72.656  Millions
Inhibikase Therapeutics Inc   14.89 $ 87.666  Millions$ 5.887  Millions
Maze Therapeutics Inc   13.29 $ 264.541  Millions$ 19.900  Millions
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Imagenebio Inc   13.06 $ 95.642  Millions$ 7.324  Millions
In8bio Inc   13.04 $ 13.226  Millions$ 1.014  Millions
Pharmacyte Biotech Inc   12.67 $ 13.440  Millions$ 1.061  Millions
Protara Therapeutics Inc  12.52 $ 122.216  Millions$ 9.761  Millions
Taysha Gene Therapies Inc   12.34 $ 312.761  Millions$ 25.349  Millions
Cargo Therapeutics Inc   12.08 $ 252.567  Millions$ 20.908  Millions
Aura Biosciences Inc   11.94 $ 177.311  Millions$ 14.852  Millions
Kalaris Therapeutics Inc   11.56 $ 88.426  Millions$ 7.651  Millions
Entera Bio Ltd   11.28 $ 10.858  Millions$ 0.963  Millions
Prokidney Corp   10.77 $ 294.728  Millions$ 27.359  Millions
Engene Therapeutics Inc   10.68 $ 201.913  Millions$ 18.913  Millions
Titan Pharmaceuticals Inc   10.66 $ 2.803  Millions$ 0.263  Millions
Century Therapeutics inc   10.43 $ 155.843  Millions$ 14.948  Millions
Acumen Pharmaceuticals Inc   10.42 $ 143.369  Millions$ 13.753  Millions
Neumora Therapeutics Inc   10.41 $ 217.588  Millions$ 20.897  Millions
Leonabio Inc   10.00 $ 29.823  Millions$ 2.981  Millions
Cullinan Therapeutics Inc   9.96 $ 265.482  Millions$ 26.664  Millions

Date modified: 2026-08-29T17:31:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.